APA (7th ed.) Citation

A, A. S., V, Q., L, S., F, R., & N, M. (2026). Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence. Pharmaceuticals (Basel, Switzerland), 19(6), . https://doi.org/10.3390/ph19060833

Chicago Style (17th ed.) Citation

A, Abu Suleiman, Quagliariello V, Spadafora L, Russo F, and Maurea N. "Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence." Pharmaceuticals (Basel, Switzerland) 19, no. 6 (2026). https://doi.org/10.3390/ph19060833.

MLA (9th ed.) Citation

A, Abu Suleiman, et al. "Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence." Pharmaceuticals (Basel, Switzerland), vol. 19, no. 6, 2026, https://doi.org/10.3390/ph19060833.